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Introduction
The best individual treatment for patients with malignant 
pleural mesothelioma (MPM) is discussed controversially 
in the last decades although increasing knowledge has 
been generated over time. In particular many “expert 
opinions” are currently circulating upon the role of 
extrapleural pneumonectomy (EPP) for MPM (1-5). 
The lack of evidence for answering this specific topic is 
mainly due to the fact that MPM is a rare disease and 
characterized by its heterogeneity in clinical presentation 
and biological behavior. This makes it difficult to perform 
studies addressing these surgical questions within a realistic 
time frame. Furthermore, the reporting of outcome data 
after surgical interventions especially morbidity is less 
standardized than after medical treatment. The present 
article aims to review the current literature focusing 
on short- and long-term outcome after EPP embedded 
in multimodality treatment concepts. It presents our 
perspective regarding the role of EPP, which is based on 
clinical experience accompanied with critical analysis of our 
own data as well as the literature and our interaction with 
other specialists worldwide.
Short-term outcome: 30- and 90-day mortality, 
morbidity
The value of surgical resection of MPM even in a 
multimodality concept is debated since no randomized 
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trials have answered this question until now. Under these 
circumstances of a debatable benefit it is particularly 
important, that this intervention is as harmless as possible 
for the patient. The criticism of an exceedingly high 
mortality rate of EPP came up after publication of the 
results of the Mesothelioma and Radical Surgery (MARS) 
trial where surgical mortality in a small case series of 
19 patients was 10.5%. However, this is not supported by 
recently reported EPP trials for trimodality therapy showing 
a 30-day mortality in a range of 2–5% in experienced 
centres (Table 1) (21). But taking into account all studies 
published between 1985–2010 a wide range of 0 to a maximum 
of 11.8% mortality is reported (22) at 30-day. This means that 
an EPP can be performed relatively safely by experienced 
surgeons in a well selected patient population. Reporting 
mortality at 30-day in these often very sick patients with 
multiple co-morbidities and after a complex operation 
might not be sufficient, whereas 90-day mortality seems to 
be more representative. Table 1 summarizes mortality rates 
reported in studies with more than 100 patients undergoing 
EPP. It has to be taken into account, that in these larger 
series also patients with higher risk profiles were accepted 
for surgery.
Not surprisingly, morbidity after an EPP is very frequent 
and the prevention but also the efficiency of its management 
depends highly on the centers’ experience (Table 2). 
Surgery is performed often after an induction therapy in 
patients with usually a higher tumor load, sometimes with 
infiltration into the chest wall. The procedure harbors a 
relevant risk for technical complications. This includes 
risk of postoperative hemorrhage due to a large resection 
surface, empyema because the procedure takes many hours, 
failure at the reconstructed diaphragm or pericardium 
sites, but also, atrial fibrillation, frequently seen after lung 
resection, pneumonia or ARDS, and many more. Morbidity 
rates reported after EPP are extremely variable because of 
variation in definition of morbidity, being major or minor 
or life-threatening or other. In the following paragraph, 
the morbidity profile after EPP will be discussed. Table 3 
summarizes the most frequent complications reported after 
EPP representing only studies with more than 100 patients 
after EPP.
Whereas atrial fibrillation represents a very frequent, 
reversible and relatively easily manageable problem, 
bronchopleural fistula and subsequent empyema, ARDS, 
or patch failure resulting in gastric herniation are severe 
postoperative complications. The frequency of empyema 
varies considerably in the literature between 3–30%. This 
might be related to the fact, that some series do not report 
about late empyema, which is to our experience the most 
frequent form of empyema occurring several weeks after 
the operations when patients already returned home or 
were transferred to rehabilitation institutions. Over the 
past decades we can report positive outcome after our 
accelerated empyema treatment with repetitive debridements 
and subsequent VAC treatment, where the chest was 
definitively closed within 8 days in 95% of the patients (26). 
Whereas bleeding complication and patch failures are more 
technical complications and should be avoided, pulmonary 
embolism and ARDS are difficult to predict or to avoid 
and contribute in most series to the lethal complications. 
For this reason, some centers recommend preoperative 
screening for deep venous thrombosis (27), or temporary 
postoperative therapeutic anticoagulation (10). For those 
centers offering induction chemotherapy to their patients, 
the perioperative anesthesiological protocol is critical as it 
has been well documented that high intraoperative FiO2 
triggers postoperative ARDS (28). The management can 
be very challenging in a pneumonectomized patient and—
as depicted in Table 4—it has been demonstrated that the 
centers’ experience plays a crucial role here. Centers with less 
than 5 EPP per year have a significant higher incidence of 
postoperative ARDS (23). Centers offering ECLS programs 
provide certainly more experience in handling these patients.
In general, it has been reported from the same STS 
database, that the center volume influences significantly 
morbidity and mortality after MPM surgery in univariate 
analysis (Table 2).
Quality of life (QoL)
For obvious reasons, deterioration of QoL after this 
operation is a big concern for the patient as well as the 
physicians. This is especially important because life 
expectancy is limited in MPM patients and the QoL in this 
remaining time should be as good as possible. However, 
tumor progression is also substantially interfering with 
QoL and this has to be taken into account when data 
are interpreted. In Table 5 three studies are summarized 
reporting QoL after EPP.
All studies report QoL below baseline after EPP, some 
until after 12 months after the operation (5), or even 
19 months (21), whereas others report return to baseline 
after 6 months (29). In a recent analysis of our own 
cohort of patients undergoing induction chemotherapy 
in a 2-year period of time, patients filled out the EORTC 
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Table 3 Common complications after EPP [adapted from Taioli et al. (24). Meta-analysis of survival after pleurectomy decortication versus 
extrapleural pneumonectomy in mesothelioma] (including studies with 100 or more EPPs completed)
Publication
No. of patients 
in study
No. of EPPs 
completed
Overall morbidity Complications [n]
Mordant et al., 2016 (6) 126 126 CTX: 29.7%, IMRT: 35.5% AF [21]
Sharkey et al., 2016 (7) 362 133 37.15% AF [29], BPF [9], PE [3], PF [11]
Stahel et al., 2015 (8) 151 113 NR BPF [4], PE [3]
Bovolato et al., 2014 (9) 1,365 301 21.6% AF [32], ARDS [1], BPF [3], DVT [2], PE [3], PF [3]
Lauk et al., 2014 (10) 251 251 major: 30% AF [67], ARDS [3], BPF [20], PE [9], PF [12]
Spaggiari et al., 2014 (12) 518 518 major: 26.3% AF [18.7%], BPF [14]
Flores et al., 2008 (25) 663 385 NR DVT [3], PE [6]
Rice, 2007 (18) 100 100 73% ARDS [8], BF [2], DVT [3], PE [1], PF [3]
Sugarbaker et al., 1999 (20) 183 183 50%, major: 24.5%,  
minor: 41%
AF [68], DVT [4], PE [3], PF [2]
AF, atrial fibrillation; ARDS, adult respiratory distress syndrome; BPF, bronchopleural fistula; DVT, deep vein thrombosis; PE, pulmonary 
embolism; PF, patch failure; EPP, extrapleural pneumonectomy; IMRT, intensity-modulated radiotherapy; CTX, chemotherapy; NR, not reported.
Table 4 Morbidity and Mortality after EPP—STS-GTD (n=225) [adapted from Burt et al., JTCVS 2014 (23)]
Characteristic
EPP
≥5/y <5/y P value
Cases 31 (32.6) 64 (67.4) <0.001
ARDS 0 (0.0) 8 (12.5) 0.050
ARDS, adult respiratory distress syndrome; EPP, extrapleural pneumonectomy.
Table 5 QoL reported in literature
Publication Study design
No. of 
patients in 
study
Modalities
No. of EPPs 
completed
Mortality
Overall 
morbidity
QoL
Rena et al., 
2012 (5)
Retro 77 ind. CTX (n=64), 
adj. CTX (n=13)
40 30 d: 5% 62% Below baseline after 6 & 12 months
Treasure et al., 
2011 (21)
Prospective 50 ind. CTX ± adj. 
therapy
19 30 d: 10.5%, in-
hospital: 15.8%
69% Below baseline after 6 weeks, 3, 6, 9, 
12, 18 & 19 months
Weder et al., 
2007 (29)
Prospective 61 ind. CTX ± adj. 
RT
45 30 d: 2.2% Major: 
35%
Overall QoL was less impaired after 
surgery, though it did not reach the 
baseline level 6 months thereafter
EPP, extrapleural pneumonectomy; QoL, quality of life; CTX, chemotherapy.
Table 2 Morbidity and mortality after EPP—STS-GTD (n=225) [adapted from Burt et al., JTCVS 2014 (23)]
Event
Univariate Multivariate
OR (95% CI) P value OR (95% CI) P value
Procedure (EPP) 6.99 (2.73–17.90) <0.001 6.51 (2.07–20.47) 0.001
Center volume <5 procedures/y 3.42 (1.52–7.70) 0.002 1.38 (0.49–3.93) 0.54
EPP, extrapleural pneumonectomy.
Annals of Translational Medicine, Vol 5, No 11 June 2017 Page 5 of 8
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2017;5(11):237atm.amegroups.com
QLC-C30 and -C15 and SF-36 self-rating questionnaires 
preoperatively, 6 weeks, and 4 months after the operation. 
Interestingly, some symptoms such as general health 
score, vitality, social functioning, and mental health were 
even better 4 months after the operation compared to 
preoperatively (unpublished data). This might be related to 
the fact, that entrapped lung is resected.
Long-term outcome
The most important parameter for evaluating an 
oncological treatment concept in MPM is overall survival 
(OS). It is well known, that the biological behavior of MPM 
is very heterogeneous and that clinical staging is much less 
accurate and reproducible than in other tumor entities. 
These two facts make it very difficult to describe precisely 
a patient cohort which undergoes treatment. Therefore, a 
comparison between case series and interventions should 
be done cautiously. However, the different reports in the 
literature describe a realistic scenario which allows some 
conclusions.
The role of EPP in treatment of MPM has been heavily 
criticized after the release of the MARS I trial (21). The 
MARS I trial concluded that “EPP within trimodal therapy 
offers no benefit and possibly harms patients” although only 
16 patients of 24 patients assigned to the EPP arm received 
radical surgery. The study was not designed to answer 
the question of benefit or not of EPP but rather of the 
feasibility of such a trial. A definitive answer to this question 
would need an accrual of 670 patients to identify a survival 
benefit, as we have addressed these critical facts together 
with other experts (30).
OS data are within a comparable range in most series 
of multimodality treatment and reach usually a plateau 
at about 18–22 months median OS. Again it depends 
substantially on patient selection and subset analysis creates 
much more favorable outcome data. Table 1 summarizes 
the results from several centers reporting OS of patients 
undergoing multimodality treatment including EPP.
The biggest surgical  database from the IASLC 
including 1,494 patients treated with surgery with curative 
intent, suggested a possible OS benefit in patients with 
stage I undergoing EPP with 40 months compared with 
23 months after P/D (Figure 1). Based on these data, we 
should recommend EPP for stage I MPM. However, this 
has not gained support in current practice where most 
centers perform P/D in patients with little tumor load and 
reserve EPP for patients with advanced disease especially 
with fissure involvement.
Progression free survival (PFS) is rarely reported in the 
literature and difficult to assess in MPM patients because 
the interpretation of a follow-up CT or PET CT after the 
surgical intervention is highly variable (as are the follow-
up algorithms), as the differentiation between a regular 
postoperative change or a tumor recurrence can only be 
documented with repetitive scans and clear growth over 
time.
Recommendations
For many years, EPP was considered to be the only surgical 
procedure which achieves a macroscopic complete resection 
(MCR) and it was applied in operable patients independent 
of stage and histology. In some individuals with very early 
disease, a P/D was performed in order to preserve the lungs. 
Since OS of patients after P/D is not different compared to 
EPP, most groups started a transition from EPP to P/D in 
the majority of patients over the last years. However, as in 
Figure 1 Survival after EPP (IASLC database) (15). EPP, extrapleural pneumonectomy; P/D, pleurectomy/decortication.
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other malignancies, one procedure does not fit for all and 
there are situations, in which a patient may require an EPP 
in order to obtain a MCR and still have a “functioning” 
lung left behind.
This can be anticipated from the CT scan, but final 
decision is sometimes been made during surgery only. 
This is typically the case in tumors with relevant lung 
parenchyma infiltration (as depicted in Figure 2) and 
preferentially on the left side were an EPP is usually better 
tolerated. Another argument for EPP is the concept applied 
in the SMART trial (1) with neoadjuvant hemithoracic 
radiotherapy followed by EPP reporting surprisingly good 
OS which cannot be explained by patient selection alone.
Therefore, patients foreseen for a P/D should be 
prepared to undergo EPP in case of extensive lung 
infiltration discovered during surgery. Not only during 
patients informed consent discussion, the patient should 
be informed about EPP but also preoperative functional 
assessments have to be performed accordingly. Pulmonary 
function testing showing a forced expiratory volume in 1 
second (FEV1) of greater than 2 L is generally adequate for 
pneumonectomy for nearly all patients (32). Quantitative 
ventilation/perfusion scanning should be performed and 
predicted postoperative (PPO) FEV1 (ideally more than 
1.2 L) be calculated in all patients. If both, FEV1 and 
DLCO are above 80%, resection up to pneumonectomy 
is feasible without any further investigation (32). Cardiac 
assessment should be performed in function of the patients’ 
comorbidities, some centres advise routine echography for 
all patients undergoing EPP in order to rule out pulmonary 
hypertension.
If early disease should be treated by EPP remains an 
open question, although data from IASLC are suggestive. 
In conclusion, patients with MPM who are treated in 
a multidisciplinary concept including MCR, should be 
discussed with a nuanced view in which lung preservation 
should be achieved whenever possible, but an EPP may be a 
valuable solution in selected cases.
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